 Virpax Pharmaceuticals Inc. NASDAQ: VRPX said on Tuesday it received a written pre-IND investigational new drug response from the U.S. FDA Food and Drug Administration for MMS019 that supports further research on its application as an intranasal protective that restricts transmission of viruses to others. Virpax to seek an NDA for MMS019 The Pennsylvania-based company ... The post Heres why Virpax Pharmaceuticals is up 280 on Tuesday appeared first on Invezz. 